Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Bacterial Infections
Interventions: Debio 1450, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemostasis
Interventions: HEMOBLAST Bellows; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: 21 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Chapel Hill, North Carolina • Danville, Virginia

Conditions: Healthy
Interventions: JTK-853 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: AZD8630, Placebo, Inhaler; Drug · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 45
States / cities: Mesa, Arizona • Huntington Beach, California • La Mesa, California + 41 more

Conditions: Suicide, Surveillance, Mental Health, Substance Use, Depressive Symptoms
Interventions: New Hope (NH), Elders Resilience (ER), Case Management (CM); Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 16 Years to 29 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Primary Axillary Hyperhidrosis
Interventions: Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of Sham Patch; Device
Lead sponsor: Candesant Biomedical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Fremont, California • Rockville, Maryland + 6 more

Conditions: Safety and Tolerability in Healthy Volunteers
Interventions: IgG Binding Protein LT, Placebo; Dietary Supplement
Lead sponsor: Bactolife A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Keratoconjunctivitis
Interventions: Dupilumab; Drug
Lead sponsor: Andover Eye Associates; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 20
States / cities: Los Angeles, California • Littleton, Colorado • Hollywood, Florida + 17 more

Conditions: Healthy Volunteer, Becker Muscular Dystrophy
Interventions: EDG-5506, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Crohn Disease
Interventions: Guselkumab, Risankizumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 41
States / cities: Dothan, Alabama • Mobile, Alabama • Anaheim, California + 33 more

Conditions: Osteoarthritis
Interventions: AGG-523 (Aggrecanase Inhibitor); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 55 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Boston, Massachusetts • Newton, Massachusetts • Winchester, Massachusetts + 1 more

Conditions: Dermatitis, Atopic
Interventions: MK-6194, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more

Conditions: Charcot-Marie-Tooth Disease
Interventions: NMD670, Placebo; Drug
Lead sponsor: NMD Pharma A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Kansas City, Kansas • Boston, Massachusetts • Columbia, Missouri + 5 more

Conditions: Benign Prostatic Hyperplasia
Interventions: tadalafil, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Greenwood, Indiana

Conditions: Migraine
Interventions: Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encino, California + 23 more

Conditions: Non-Exudative Age Related Macular Degeneration
Interventions: MC-1101, MC-1101 Vehicle; Drug
Lead sponsor: MacuCLEAR, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Parkinson's Disease
Interventions: DNS-7801 (low-dose), DNS-7801 (high dose), Placebo; Drug
Lead sponsor: Dart NeuroScience, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 9
States / cities: Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more

Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions: PLS240, Placebo, Open-Label Extension PLS240; Drug
Lead sponsor: Pathalys Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 49
States / cities: Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more

Conditions: Post-menopausal Vasomotor Symptoms
Interventions: ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID, Placebo; Drug
Lead sponsor: Acer Therapeutics Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Hypertension, Pulmonary
Interventions: PF-00489791, placebo, sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more

Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine SR, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 5
States / cities: Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more

Conditions: Pain
Interventions: MEB-1170, Placebo; Drug
Lead sponsor: Mebias Discovery, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

A Single Dose Study of Debio 1450 in Healthy Subjects

HEMOBLAST Pilot Clinical Investigation

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

Southwest Hub for American Indian Youth Suicide Prevention Research

Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Safety and Tolerability Evaluation of IgG Binding Protein LT

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration

DNS-7801 vs. Placebo in Parkinson's Disease

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

A Study to Assess the Safety of MEB-1170 in Healthy Subjects